|
|
 |
|
Viewing report
|
|
|
|
Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D -- Companies Products and WW Market, 2004-2009
Takeda Pacific, July 2005, Pages: 168
One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness.
Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.8 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.
The study projects the 5-year trends for biomarkers, molecular diagnostics and pharmacogenomic tests used by the drug makers. The report charts the developments of more than 50 companies involved in this dynamic industry.
This report discusses new FDA initiatives to accelerate the approvals of emerging diagnostics and new drugs by integrating biomarkers and pharmacogenomic tests drug development from pre-clinical through the end of clinical trial phases. Companies have responded with new products. Roche’s new microarray test, targets certain gene variants, and tests if patients respond well to 30 or more currently marketed drugs. Tailored therapies such as Herceptin, Gleevec, Erbitux, or Irressa are among a new class of marketed products. They work very effectively, but just for a sub-set of individuals that pass special genetic tests designed for each product. These products signal that the era of personalized medicine has begun.
This study is packed with interesting data and includes more than 66 figures and tables. The tables provide data about technologies, companies, product pipelines, partnerships and more. The study also has additional data such as the worldwide incidence and prevalence of major diseases. The report analyzes partnering deals and includes several years of alliance and M&A data.
Twenty-two selected companies are profiled, with details including contact information, business and product overviews, alliances and patent or other financial details. This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.
Customers who bought this item also bought
Biomarkers and Tests for Pharma/ Biotech R&D – Companies Products and WW Market, 2006-2011
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Biomarkers: The Future of Next-Generation Drug R&D
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
Molecular Diagnostics 2007: Technologies, Companies, Products, Applications and WW Outlook
Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases
Molecular Diagnostics 2007: Technologies, Companies, Products, Applications and WW Outlook
Molecular Diagnostics Markets
Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market
|
|
|
|
